Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. (16th April 2018)

• Record Type: Journal Article
• Authors: Sanagawa, Akimasa; Hotta, Yuji; Kataoka, Tomoya; Maeda, Yasuhiro; Kondo, Masahiro; Kawade, Yoshihiro; Ogawa, Yoshihiro; Nishikawa, Ryohei; Tohkin, Masahiro; Kimura, Kazunori
• Is Part Of: Cancer medicine. Volume 7:Number 6(2018:Jun.)
• Page Start: 2269
• Page End: 2279
• Publication Date: 2018-04-16
• Subjects: Cancer chemotherapy -- data mining -- FDA Adverse Event Reporting System -- hepatitis B virus -- signal detection; 616.994005
• DOI: 10.1002/cam4.1429
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B infection were retrieved from the FAERS database. The reporting odds ratio (ROR) was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. We detected statistically significant risk signals of hepatitis B for 33 of 64 anticancer agents by ROR (26 cytotoxicity drugs and seven molecular‐targeted drugs). We focused on molecular‐targeted drugs and assessed the risk of hepatitis B from specific anticancer drug combinations. The frequency of hepatitis B infection was significantly high for drugs such as rituximab, bortezomib, imatinib, and everolimus. The addition of cyclophosphamide, doxorubicin, and fludarabine to drug combinations additively enhanced the frequency of hepatitis B infection. There were no reports on hepatitis B infection associated with trastuzumab or azacitidine monotherapy. However, trastuzumab‐containing regimens (e.g., combinations with docetaxel or paclitaxel) were correlated with the incidence of hepatitis B infection, similar to azacitidine monotherapy. Our findings suggest that the concomitant use of anticancer drugs, such as trastuzumab, taxane, and azacitidine, may contribute to the risk of hepatitis B infection. The unique signals detected from the public database might provide clues to eliminate the threat of HBV in oncology. Abstract : The FAERS database was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. A potential risk of hepatitis B infection in treatments involving azacitidine or trastuzumab and taxane combinations was found, and the unique signals detected from the public database might provide clues to eliminate the threat of HBV in oncology.